Keith Kerman, M.D. is an Operating Partner and Senior Advisor with The Riverside Company, a global private equity firm focused on growth businesses. Dr. Kerman has 20 years of experience in healthcare related private equity, venture capital, and operating roles, and has been an executive, investor, and board member at numerous healthcare businesses and organizations. Prior to joining Riverside, Dr. Kerman was a Managing Director and led the healthcare practice at Primus Capital Funds, a growth equity and middle market buyout firm, and was previously a General Partner with Morgenthaler Ventures. Dr. Kerman also was an operating executive at U.S. Healthcare, where he was president of the company’s subsidiary providing managed care services to self-funded health plans. Prior to joining U.S. Healthcare, he was a Robert Wood Johnson Foundation Clinical Scholar at the University of Pennsylvania, was a member of the clinical faculty at the Hospital of the University of Pennsylvania, and was a Senior Fellow at the Leonard Davis Institute for Health Economics at The Wharton School. He has an AB and an MD from Brown University, and an MBA from The Wharton School of the University of Pennsylvania. Dr. Kerman currently serves on the Board of Directors of AxioMed Spine Corporation, Cleveland Heart Labs, IDOC, and Physicians Pharmacy Alliance. He also serves on the Worldwide Board of Directors of the Healthcare Information Management Systems Society (HIMSS), is a member of the Cleveland Clinic Innovations Industrial Advisory Board, and is Chairman of the Advisory Board of the Cleveland Clinic’s Global Cardiology Innovation Center.
William T. Abraham, MD
Professor of Internal Medicine and Physiology and Cell Biology Chief, Division of Cardiovascular Medicine Deputy Director, The Dorothy M. Davis Heart & Lung Research Institute, The Ohio State University
William T. Abraham, M.D., F.A.C.P., F.A.C.C. is Professor of Internal Medicine and Chief of the Division of Cardiovascular Medicine at The Ohio State University College of Medicine. He also serves as Deputy Director of the Dorothy M. Davis Heart and Lung Research Institute. Dr. Abraham earned his medical degree from Harvard Medical School in Boston, Massachusetts, following which he completed his residency in Internal Medicine and fellowships in Cardiology and Heart Failure/Cardiac Transplantation at the University of Colorado Health Sciences Center. He previously held faculty appointments at the University of Colorado, the University of Cincinnati, and the University of Kentucky. He is board certified in Internal Medicine and in Cardiovascular Diseases. Dr. Abraham’s research interests include the role of the kidney in heart failure, neurohormonal mechanisms in heart failure, sleep disordered breathing in heart failure, and clinical drug and device trials in heart failure and cardiac transplantation. Dr. Abraham has received grants from the National Institutes of Health, the American College of Cardiology, and the Aetna Quality Care Foundation and has participated as Principal Investigator in more than 100 multicenter clinical drug and device trials. In addition to authoring more than 600 original papers, abstracts, book chapters, and review articles, Dr. Abraham has co-edited a leading textbook on heart failure entitled Heart Failure: A Practical Approach to Treatment. Dr. Abraham serves on the editorial boards of several major journals including Congestive Heart Failure and Journal Watch Cardiology. He is also a scientific reviewer for such publications as Circulation, the European Heart Journal, and the Journal of the American College of Cardiology. Dr. Abraham has been recognized as one of the “Best Doctors in America” for six consecutive years.
Dorothy H. Air, PhD is Associate Vice President for Entrepreneurial Affairs and Technology Commercialization at the University of Cincinnati. Her primary responsibilities include assisting faculty in start-up company activity related to new technology development; developing a network of commercialization/business resources for the university; and developing entrepreneurial programs to promote entrepreneurship in the university and community. Her accomplishments include: PI on a Pre-seed Fund grant by ODOD Third Frontier Program for $1.1 million; PI on a $600,000 NSF Grant, Cincinnati Creates Companies, which includes an educational and mentoring program for entrepreneurs and a business plan competition; Senior Investigator on a $27 million grant from ODOD Third Frontier to establish the Center for Computational Medicine; and Senior Investigator on $10 million NIH Poc-Cent grant. Other past accomplishments include: development of the UC Launch Pad to provide gap funding and mentoring to advance the most promising research technologies and co-founder of SoundingBoard. Dr. Air serves on the Boards of Hamilton County Business Center and the Greater Cincinnati Venture Association and is a past Board member of BIO/START and Edison Materials Technology Center (EMTEC). Dr. Air was the initiator of the Ohio Valley Affiliates for Life Sciences (OVALS), a consortium of five universities in Ohio, Kentucky and West Virginia to create university-industry networking opportunities and visibility for the research and commercialization capabilities in the region. She has served as the chair of the effort for the last ten years. In 2005, she was appointed by the University of Cincinnati as a loaned executive to CincyTechUSA, where she serves as vice President of Operations for CincyTechUSA for part of her time. Her responsibilities at CincyTech include developing entrepreneurial resources and identifying and developing technology business opportunities. She was a member of the 3-person leadership team that developed CincyTech’s original Entrepreneurial Signature Program Proposal, which received a $14.8 million award from the State of Ohio. She is currently in the process of launching a University of Cincinnati Technology Commercialization Center, which has received partial funding from the Third Frontier. In 2006, she was recognized by Women’s Business Cincinnati as one of the Top 10 Women in Technology in the Cincinnati Region, and she is the recipient of the 2007 Leading Women of Greater Cincinnati for Entrepreneurship. Dr. Air serves on the Greater Cincinnati/Northern Kentucky Airport Board, an entity of significant regional economic importance.
Mike joined Early Stage Partners (ESP) as Managing Director in 2008 to lead investments in the life science sector. With prior M&A roles for strategic acquirers, Mike provides medical startups and entrepreneurs assistance toward a successful exit through hands on investing. He currently serves on the board of several private companies, including CardiOx (stroke diagnostic), GenSyn Technologies (pharmaceutical manufacturing), Great Lakes Pharmaceuticals (catheter lock solution), and Juventas Therapeutics (regenerative medicine). Mike also sits on the Commercialization Advisory Board for the Global Cardiovascular Innovation Center helping make grant decisions to Ohio’s leading early-stage medical technologies. Prior to joining ESP, Mike served as director of corporate acquisitions for C.R. Bard (NYSE: BCR), where he developed the business development process leading to the company’s most acquisitive time in their history. Mike also managed a field sales force and negotiated hospital contracts for a Bard division. Mike worked at Medtronic (NYSE: MDT) where he first led a $750 global product launch in cardiac rhythm management. He then served in Medtronic’s Corporate Development group and was for responsible many successful minority investments, divestitures and acquisitions. Mike is a graduate of Miami University in Ohio and holds an MBA from the Kellogg Graduate School of Management at Northwestern University.
Paul DiCorleto, PhD
Chairman, Cleveland Clinic Lerner Research Institute
Dr. Paul E. DiCorleto is Chair of the Cleveland Clinic Lerner Research Institute (LRI), and Professor and Chair of the Department of Molecular Medicine, Case School of Medicine. The LRI is home to over 190 principal investigators and 1500 employees performing biomedical research. Dr. DiCorleto received his undergraduate training in chemistry at Rensselaer Polytechnic Institute and his doctorate in biochemistry from Cornell University. Dr. DiCorleto’s research, which has been continuously funded by NIH for over 30 years, focuses on the molecular and cellular basis of atherosclerosis. He has been with the Cleveland Clinic for 30 years, having served previously as Chairman of the Department of Cell Biology, and as an Associate Chief of Staff. He is currently a member of the Clinic’s Board of Governors and Board of Trustees. On a national level, he has chaired multiple NIH and American Heart Association review panels, as well as several national conferences on research into heart and vascular disease. He has published over 100 articles in his field and serves on the editorial board of multiple scientific journals. Dr. DiCorleto is a Community Trustee of Cleveland State University and a member of the Association of American Medical College’s Advisory Panel on Research. He is also a director of Cleveland BioLabs, Inc. (CBLI) – a publicly traded, Cleveland Clinic spin-off company.
For over 30 years, Bob Easton, Chairman of Bionest Partners, has been recognized as a leader in healthcare business consulting. He has built and led two top firms, beginning with the founding of The Wilkerson Group in 1985. He has led scores of market development and strategic advisory assignments for clients, including large and specialty pharmaceutical companies, early-stage through publicly traded biopharmaceutical companies, and diagnostics businesses. He has influenced the decision-making of numerous healthcare professionals and supported hundreds of client executives in Australia, Japan, Canada, U.S., Europe, and Israel. His interest in healthcare began when he managed a medical diagnostics business for Union Carbide. Mr. Easton has been highly visible in the industry, having written and spoken about multiple industry issues in scores of venues. He is Chairman of the New York Biotechnology Association (NYBA). He has served on eight medical company Boards including Apex Bioventures, CollaGenex, and Cepheid. He also serves as Chairman of Gilda’s Club of New York City, which provides social and emotional support to people living with cancer. Mr. Easton holds two degrees in Chemical Engineering from Rice University and an MBA from the Harvard Business School.
Paul W. Erhardt, PhD
Professor Medicinal & Biological Chemistry, College of Pharmacy & Pharmaceutical Sciences; Joint Professor Biochemistry & Cancer Biology, College Medicine & Life Sciences; Director, Center for Drug Design and Development (CD3), The University of Toledo
Dr. Erhardt has been the director of the University of Toledo Center for Drug Design and Development since its inception in 1994. His involvement encompasses all aspects of pharmaceutical research and development, ranging from the design and synthesis of small-molecule therapeutics to the advanced clinical study of marketed drugs and diagnostic agents. In this capacity, the CD3 participates in a wide range of collaborative research activities throughout the University of Toledo and surrounding medical research community. Dr. Erhardt received his PhD in Medicinal Chemistry from the University of Minnesota and conducted his post-doctoral research at the University of Texas at Austin.
Dr. Peter Fitzgerald is the Director of the Center for Cardiovascular Technology and Director of the Cardiovascular Core Analysis Laboratory (CCAL) at Stanford University Medical School. He is an Interventional Cardiologist and has a PhD in Engineering. He is Professor in both the Departments of Medicine and Engineering at Stanford. Presently, Dr. Fitzgerald’s laboratory includes 14 postdoctoral fellows and graduate engineering students focusing on state-of-the-art technologies in Cardiovascular Medicine. He has led or participated in over 95 clinical trials, published over 300 manuscripts/ chapters, and lectures worldwide. Peter has been principle/founder of eleven medical device companies in the San Francisco Bay Area. He has transitioned eight of these start-ups to large medical device companies. He serves on several boards of directors, advised dozens of medical device startups as well as multinational healthcare companies in the design and development of new diagnostic and therapeutic devices in the cardiovascular arena. In 2001, Peter co-founded LVP Capital, a venture firm, focused on medical device and biotechnology start-ups in San Francisco.
Jan Garfinkle utilizes her educational background in biomedical engineering, extensive medical device operating experience and industry connections to select and nurture outstanding companies. Jan led Arboretum’s investment in HandyLab and served on the Board of Directors for five years until the company was acquired by Becton Dickinson. She has also led Arboretum’s investments in CardioMEMS, Uptake Medical, BAROnova, Vasonova, Esperion, NXThera, Sonitus Medical, Cerêve and MSC. She presently serves as a director of NXThera, Sonitus, Cerêve and MSC, and as a board observer on Uptake Medical and Esperion. Jan heads the fundraising efforts at Arboretum and is a member of the Investment Committee. Jan founded the firm in 2002 and has been actively investing since. Prior to founding Arboretum in 2002, Jan spent 20 years in senior management positions within entrepreneurial healthcare companies. She worked for two successful medical device start-up companies, Advanced Cardiovascular Systems (ACS) and Devices for Vascular Intervention (DVI). Each of these companies was acquired by Eli Lilly for more than $100 million and became the foundation for Guidant Corporation. She joined each company early in its development and held key management roles in marketing, clinical research, and sales and successfully launched over 20 new medical products. She began her career as a manufacturing engineer and production line manager for Procter and Gamble. Jan is the past President of the Michigan Venture Capital Association, an Advisory Board member of the Global Cardiovascular Innovation Center (GCIC) at the Cleveland Clinic, and a member of the Healthcare Advisory Board at the University of Michigan. Jan also serves as a member of AdvaMed’s National Venture Capital Advisory Board. Jan earned a BS in Bioengineering from the University of California at Berkeley and an MBA from the Wharton School at the University of Pennsylvania.
Jeff Gold is President and Chief Operating Officer of Myoscience, Inc., an innovation-driven medical technology company based in Silicon Valley, California. Mr. Gold was most recently the President and CEO of Velomedix Inc, a venture backed company that developed a unique technology for rapidly inducting therapeutic hypothermia in patients undergoing severe acute cardiovascular events, such as heart attack and cardiac arrest. Previously, he was a Venture Partner of Longitude Capital where he focused on investments in medical devices. Prior to Longitude, Mr. Gold was Chief Executive Officer of CryoVascular Systems, a medical device company developing treatments for peripheral vascular disease, from 2001 to 2005. CryoVascular was acquired by Boston Scientific Corporation in 2005. Between 1997 and 2000, Mr. Gold was COO and Executive Vice President of CardioThoracic Systems, a medical device company focused on developing products to enable off-pump open-heart surgery. CTSI completed an IPO in 1996 and was subsequently acquired by Guidant Corporation. Prior to CTSI, Mr. Gold spent 18 years with Cordis Corporation, the primary cardiovascular device subsidiary of Johnson & Johnson. While at Cordis he co-founded Cordis Endovascular Systems, a subsidiary focused on developing technologies for treating patients experiencing, or at risk of, a stroke. He currently serves on the Boards of Access Closure, AngioDynamics, Corindus, and Velomedix. He also is a member of the Executive Committee of the Center for Entrepreneurship & Innovation at the University of Florida. Mr. Gold holds an MBA from the University of Florida and a BS in Engineering from Northeastern University, and is a graduate of GE’s Manufacturing Management Program.
VP and General Manager, AF Solutions, Medtronic Cardiac Rhythm Disease Management
Reggie Groves joined Medtronic in June 2002 as the Vice President and General Manager, Patient Management. After successfully launching the new business, Reggie was asked to lead the Cardiac Rhythm Disease Management – Quality and Regulatory functions. Currently, she serves as the Vice President and General Manager of AF Solutions where she provides overall leadership and direction for AF Solutions which is focused on finding solutions to treat atrial fibrillation. Before coming to Medtronic, Reggie was the Global Managing Partner, Enterprise Services for Scient, Inc. an internet consulting group. Prior to Scient, Reggie was the CFO for Kaiser Permanente-SE Division, CFO for Egleston Children’s Hospital and SEM at McKinsey & Company. Reggie received her Master of Business Administration from Harvard Graduate School of Business. She has a Bachelor of Science in Pharmacy from the University of Florida. She is a registered Pharmacist in Florida and Tennessee. She currently sits on the board of MedMined, Inc. and the Health Advisory Group for the Medtronic Foundation. Reggie was honored with the “Women Changemaker” award by the Business Journal in 2003 and was awarded the “Wallin Award” for her leadership contributions in 2006.
Medtronic, Vice President of Business Development, Strategy and Portfolio Management
John Mack is a medical device executive who has built strong relationships with senior executives in the medical device industry and the financial community over the past 20 years. Mr. Mack has strong qualifications in business development, integration, finance, marketing, strategy, operations, and P&L management. Mr. Mack joined Medtronic in 1996. He is currently the Vice President of Business Development, Strategy and Portfolio Management for the Structural Heart Business. His responsibilities include leading strategy development and planning, portfolio management, business development, integration management, market analytics and competitive intelligence. Mr. Mack serves on numerous Boards of Medtronic investment portfolio companies. Mr. Mack previously led global Marketing for the Heart Valve Division and held various leadership roles in Finance within Medtronic. Prior to joining Medtronic, Mr. Mack worked for Arthur Andersen, LLP. Mr. Mack graduated with high distinction from the University of Minnesota with a Bachelors of Science in Business and Accounting.
Steven E. Nissen MD is Chairman of the Department of Cardiovascular Medicine at the Cleveland Clinic. Dr. Nissen came to the Cleveland Clinic in 1992. He served for 9 years as Vice-Chairman of the Department and five years as Medical Director of the Cleveland Clinic Cardiovascular Coordinating Center (C5), an organization that directs multicenter clinical trials. In 2006, he was appointed Chairman. National leadership positions include a term as President of the American College of Cardiology (ACC), the professional society representing American cardiologists (March 2006 to March 2007). Dr. Nissen has served numerous ACC committees and working groups including Education Committee, Annual Scientific Session Planning Committee, and 2 terms as Board of Trustee. Steven Nissen earned his medical degree from the Michigan University School of Medicine in Ann Arbor. He completed Internal Medicine internship and residency at the University of California, Davis in Sacramento, and Cardiology Fellowship at the University of Kentucky Medical Center in Lexington. Dr. Nissen’s research during the last two decades has focused on application of intravascular ultrasound (IVUS) imaging to the assessment of progression and regression of coronary atherosclerosis. Contributions to scientific literature include being author/coauthor of more than 350 journal articles and 60 book chapters. As a physician/scientist, Dr. Nissen consults for many pharmaceutical companies on the development of new therapies for cardiovascular disease, but maintains a longstanding personal policy of requiring companies to donate all related honoraria directly to charity so that he receives neither income, nor a tax deduction. In recent years, he has also written extensively on the subject of drug safety. In 2001, he was co-author of the first manuscript that raised concerns about the safety of rofecoxib (Vioxx), which was withdrawn from the market 3 years later. In 2005, he re-analyzed data submitted to the Food and Drug Administration (FDA) to support approval of muraglitazar, a new agent to treat diabetes and lipid disorders. Despite a recommendation by an FDA Advisory Panel to approve this new agent, Dr. Nissen’s study reported that muraglitazar doubled the risk of major adverse cardiovascular outcomes and the Agency halted approval. In 2007, he was the author of a manuscript that demonstrated that the widely used diabetes drug rosiglitazone (Avandia™) raised the risk of myocardial infarction, resulting in a “black box’ warning by the FDA 6 months later. Dr. Nissen served as a member of the CardioRenal Advisory Panel of Food and Drug Administration (FDA) for 5 years, and as Chairman of the final year of his membership. He continues to serve as Advisor to several FDA committees as a Special Government Employee. In July 2008, while serving as guest member of the Endocrine and Metabolism Advisory Panel, Dr. Nissen recommended a new approach to approval of diabetes drugs, which was ultimately adopted by the Agency in November 2008. Steven Nissen is also known for his role in public policy discussions, particularly in the area of drug safety. He has testified in both the Senate (Health Education and Labor Committee) and House of Representatives (Energy and Commerce Committee) on the need to reform the Food and Drug Administration (FDA). He was actively involved in discussions with Congress on the FDA Amendments Act of 2007 that added additional regulatory authority for the Agency. Professor Steven Nissen was selected for the Outstanding Scientist Award by the Cleveland Clinic in 2004. Cleveland Clinic Cardiovascular Medicine Fellows have awarded him the Outstanding Teaching Award, an annual recognition, on 3 occasions. He also received Award for Outstanding Contributions to Cardiovascular Research from the Gill Heart Institute of the University of Kentucky in 2004. Other awards include “Best Doctors” 2008 by Cleveland Magazine, “One of 40 most influential persons in the City of Cleveland” 2008 Cleveland Magazine, Country’s 30 “most powerful forces in Business and Finance” 2007 Smart Money Magazine, 100 Most Influential People, Scientists and Thinkers 2007 TIME Magazine.
Matt Pollman, MD
Consultant, Cardiovascular Therapeutic and Diagnostics
Matthew Pollman, consultant, has held a number of leadership positions in the development of cardiovascular therapeutics and diagnostics. He has most recently served as Medical Director, R&D, for Abbott Vascular. In this role, Dr. Pollman was the principal medical and scientific advisor for the R&D and Business Development organizations. Prior to this role, Dr. Pollman was the Director of New Ventures, Guidant Corporation where he led a multi-disciplinary in-house start-up incubator tasked with identifying, exploring and incubating through PhI/PhII clinical trials, novel therapeutic opportunities utilizing emerging device or combination product technologies. Dr. Pollman has also directed therapeutic/diagnostic target discovery and development efforts as Director of Cardiovascular Biology and Molecular Medicine for Millennium Pharmaceuticals. Dr. Pollman is a cardiologist and cardiovascular molecular biologist and has authored numerous peer-reviewed journal articles. He has served on the faculties of Harvard Medical School and Morehouse School of Medicine.
John is founder and Managing Partner of Triathlon Medical Ventures based in Cincinnati and brings 22 years of venture investing and 13 years of research and R&D management experience in biotechnology, devices, and diagnostics. John was a Managing Director of Senmed Medical Ventures from 1989 until 2003 where he was a member of the investment committee and led the emerging medical technology investment efforts. Prior to joining Senmed, John spent 13 years with Battelle Memorial Institute serving in various research, management, and business development capacities. Locally and regionally, John was among the early organizers of Bio/Start, Cincinnati’s biomedical business incubator and served as Chairman of its Board of Trustees. He is also a Chairman of the Board of BioOhio, Ohio’s life science economic development organization and serves on the board of the Global Cardiovascular Innovation Center at the Cleveland Clinic. John represents Triathlon on the boards of Akebia Therapeutics Inc., Aerpio Therapeutics and Kereos Inc., and is an observer on the board of CoLucid. He is also Chairman of the Board of Cincinnati Children’s spinoff Airway Therapeutics. John earned his BS, MS and Ph.D degrees in Microbiology and Virology from The Ohio State University.
Daniel I. Simon, MD
Chief, Division of Cardiovascular Medicine and Director,
UH Harrington-McLaughlin Heart & Vascular Institute, University Hospitals Case Medical Center; Director, Case Cardiovascular Center and Herman K. Hellerstein Professor of Cardiovascular Research, Case Western Reserve University School of Medicine
Dr. Simon is Chief, Division of Cardiovascular Medicine and Director, Harrington Heart & Vascular Institute, University Hospitals Case Medical Center; Director, Case Cardiovascular Center and Herman K. Hellerstein Professor of Cardiovascular Research, Case Western Reserve University School of Medicine. He graduated summa cum laude from Harvard College. After earning his medical degree from Harvard Medical School, he completed his internal medicine residency and cardiovascular medicine fellowship at Brigham and Women’s Hospital and interventional cardiology training at Beth Israel Hospital, Boston. He joined the faculty of Brigham and Women’s Hospital where he rose through the ranks to Associate Director, Interventional Cardiology, Brigham and Women’s Hospital, and Associate Professor of Medicine, Harvard Medical School. A recipient of numerous research awards, Dr. Simon was elected into the American Society for Clinical Investigation, Association of University Cardiologists, and the Association of American Physicians. He is a recipient of the prestigious MERIT Award from the National Heart, Lung, and Blood Institute. He is also a Fellow of the American College of Cardiology, the American Heart Association, and the Society of Cardiac Angiography and Interventions. Dr. Simon’s main area of research interest is the role of inflammation in vascular injury and repair. His research is supported by grants from the National Institutes of Health. As Director of the Ohio Cell-based Therapy Consortium-Cardiovascular, Dr. Simon is committed to advancing stem cell and regenerative medicine efforts to treat advanced heart and vascular disease. He is an active interventional cardiologist and continues to play a leading role in clinical trials investigating new devices and anti-thrombotic drugs. Dr. Simon has published extensively in peer-reviewed basic science and clinical journals. He also serves on the Editorial Boards of Circulation and Journal American College Cardiology, and recently completed a stint as Associate Editor for Circulation where he continues to serves as Guest Editor.
D. Geoffrey Vince, PHD
Chair, Department of Biomendical Engineering, Cleveland Clinic Lerner Research Institute
Geoff Vince earned his B.Sc in Medical Sciences and Chemistry from Leicester DeMontford University and his Ph.D. in Biomedical Engineering from the University of Liverpool. Coming in the early 1990s to Cleveland Clinic’s Department of Biomedical Engineering (BME), Dr. Vince pursued research in ultrasound imaging of coronary artery disease. From 1992 to 2005, he advanced from Research Fellow to Associate Staff and developed an imaging system to capture and evaluate images of the interior of the coronary artery. As a full-time scientist, he obtained and published his research findings in such well-regarded journals as Circulation, American Journal of Cardiology, and International Journal of Cardiovascular Imaging, among others. He served on Study Sections for peer review of grant proposals at the National Institutes of Health and carried forward teaching and mentoring duties for students and junior investigators. In 2005, he stepped into the corporate world and gained experience over many successful years on the international front, first as Director of Research, then Vice President for Clinical and Advanced R&D for Volcano Corporation in San Diego. These years involved broad exposure to issues of innovation, technology transfer, industry standards, and collaborative international agreements. As of mid-2011, Dr. Vince has returned to Cleveland Clinic’s Lerner Research Institute as BME Chairman, holding The Virginia Lois Kennedy Chair in Biomedical Engineering and Applied Therapeutics. An inventor/co-inventor of several biomedical systems, he has filed over 60 applications and holds 12 U.S. patents. Perhaps the most notable is one based on his early efforts at Cleveland Clinic – “Virtual Histology”; this intravascular ultrasound imaging system was later refined and commercialized into what is now Volcano’s “VH®” system, a widely used real-time imaging modality to visualize plaque composition within arteries. Thus his own experience is a sterling example of the GCIC’s aims: showing how research from a not-for-profit institution can be leveraged for translational/clinical applications and successfully commercialized for the betterment of patient care worldwide.
Dr. Wrubel has ten years of experience in venture capital and has been associated with a large number of private companies, including such now publicly traded companies as Pozen Pharmaceuticals, OraPharma, and GenVec. Prior to starting Foundation Medical Partners, Dr. Wrubel was an investment professional with Canaan Partners and more recently Highland Capital Partners, where he specialized in biotechnology and medical device investments. Dr. Wrubel serves on the board of directors of EndoGastric Solutions, Inc., CardioMEMS, Inc., IlluminOss and Circulite, Inc. Dr. Wrubel began his business career as a consultant at The Wilkerson Group, a health care-focused management consulting company. Dr. Wrubel completed a pediatric internship at Mount Sinai Medical Center in New York. He holds an A.B. from Lafayette College, an M.D. and Masters in Public Health from Tufts University, and an M.B.A. from Columbia University. Dr. Wrubel serves on the Translational Research Advisory Committee of the Muscular Dystrophy Association, and is a member of the Health Leadership Council.